12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Evolocumab: Phase III data

Top-line data from the double-blind, international Phase III DESCARTES trial in 901 patients with fasting LDL-C levels of >=75 mg/dL and fasting triglycerides of <=400 mg/dL showed that once-monthly 420 mg subcutaneous evolocumab in combination with patients' background lipid-lowering therapy met the primary endpoint of a greater percent reduction in LDL-C from baseline to week 52 vs. placebo. Amgen said the 52-week percent LDL-C reduction seen in DESCARTES was consistent with the 52-week reduction seen in the Phase II OSLER trial to treat hypercholesterolemia. In November,...

Read the full 409 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >